Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
“We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me.”
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Study results show that this treatment for refractory/relapsed multiple myeloma can provide deep, durable responses and long treatment-free...
The committee also recommended approval of a biosimilar product for p
From the Journals
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...